TY - JOUR
T1 - Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder
AU - Sylvester, Richard J.
AU - Brausi, Maurizio A.
AU - Kirkels, Wim J.
AU - Hoeltl, Wolfgang
AU - Da Silva, Fernando Calais
AU - Powell, Philip H.
AU - Prescott, Stephen
AU - Kirkali, Ziya
AU - van de Beek, Cees
AU - Gorlia, Thierry
AU - de Reijke, Theo M.
PY - 2010/5
Y1 - 2010/5
N2 - Background: Intravesical chemotherapy and bacillus Calmette-Guerin (BCG) reduce the recurrence rate in patients with stage Ta T1 urothelial bladder cancer; however, the benefit of BCG relative to chemotherapy for long-term end points is controversial, especially in intermediate-risk patients. Objective: The aim of the study was to compare the long-term efficacy of BCG and epirubicin. Design, setting, and participants: From January 1992 to February 1997, 957 patients with intermediate-or high-risk stage Ta T1 urothelial bladder cancer were randomized after transurethral resection to one of three treatment groups in the European Organization for Research and Treatment of Cancer Genito-Urinary Group phase 3 trial 30911. Intervention: Patients received six weekly instillations of epirubicin, BCG, or BCG plus isoniazid (INH) followed by three weekly maintenance instillations at months 3, 6, 12, 18, 24, 30, and 36. Measurements: End points were time to recurrence, progression, distant metastases, overall survival, and disease-specific survival. Results and limitations: With 837 eligible patients and amedian follow-up of 9.2 yr, time to first recurrence (p <0.001), distant metastases (p = 0.046), overall survival (p = 0.023), and disease-specific survival (p = 0.026) were significantly longer in the two BCG arms combined as compared with epirubicin; however, there was no difference for progression. Three hundred twenty-three patients with stage T1 or grade 3 tumors were high risk, and the remaining 497 patients were intermediate risk. The observed treatment benefit was at least as large, if not larger, in the intermediate-risk patients compared with the high-risk patients. Conclusions: In patients with intermediate-and high-risk stage Ta and T1 urothelial bladder cancer, intravesical BCG with or without INH is superior to intravesical epirubicin not only for time to first recurrence but also for time to distant metastases, overall survival, and disease-specific survival. The benefit of BCG is not limited to just high-risk patients; intermediate-risk patients also benefit from BCG. Trial registration: This study was registered with the US National Cancer Institute clinical trials database [protocol ID: EORTC-30911]. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=77075&version=HealthProfessional&protocolsearchid=6540260.
AB - Background: Intravesical chemotherapy and bacillus Calmette-Guerin (BCG) reduce the recurrence rate in patients with stage Ta T1 urothelial bladder cancer; however, the benefit of BCG relative to chemotherapy for long-term end points is controversial, especially in intermediate-risk patients. Objective: The aim of the study was to compare the long-term efficacy of BCG and epirubicin. Design, setting, and participants: From January 1992 to February 1997, 957 patients with intermediate-or high-risk stage Ta T1 urothelial bladder cancer were randomized after transurethral resection to one of three treatment groups in the European Organization for Research and Treatment of Cancer Genito-Urinary Group phase 3 trial 30911. Intervention: Patients received six weekly instillations of epirubicin, BCG, or BCG plus isoniazid (INH) followed by three weekly maintenance instillations at months 3, 6, 12, 18, 24, 30, and 36. Measurements: End points were time to recurrence, progression, distant metastases, overall survival, and disease-specific survival. Results and limitations: With 837 eligible patients and amedian follow-up of 9.2 yr, time to first recurrence (p <0.001), distant metastases (p = 0.046), overall survival (p = 0.023), and disease-specific survival (p = 0.026) were significantly longer in the two BCG arms combined as compared with epirubicin; however, there was no difference for progression. Three hundred twenty-three patients with stage T1 or grade 3 tumors were high risk, and the remaining 497 patients were intermediate risk. The observed treatment benefit was at least as large, if not larger, in the intermediate-risk patients compared with the high-risk patients. Conclusions: In patients with intermediate-and high-risk stage Ta and T1 urothelial bladder cancer, intravesical BCG with or without INH is superior to intravesical epirubicin not only for time to first recurrence but also for time to distant metastases, overall survival, and disease-specific survival. The benefit of BCG is not limited to just high-risk patients; intermediate-risk patients also benefit from BCG. Trial registration: This study was registered with the US National Cancer Institute clinical trials database [protocol ID: EORTC-30911]. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=77075&version=HealthProfessional&protocolsearchid=6540260.
KW - Bacillus Calmette-Guerin
KW - Epirubicin
KW - Instillation therapy
KW - Isoniazid
KW - Non-muscle-invasive bladder cancer
KW - Randomized clinical trial
KW - Urothelial carcinoma of the bladder
U2 - 10.1016/j.eururo.2009.12.024
DO - 10.1016/j.eururo.2009.12.024
M3 - Article
C2 - 20034729
SN - 0302-2838
VL - 57
SP - 766
EP - 773
JO - European Urology
JF - European Urology
IS - 5
ER -